Emcure Pharmaceuticals Acquisition Intimation (NSE Reg. 30)
Emcure Pharmaceuticals Limited, a Mumbai-listed pharmaceutical company, submitted a Regulation 30 acquisition intimation to the NSE on 3 July 2026. The filing follows listed-company disclosure obligations under SEBI LODR 2015. Specific details on the target entity, acquisition price, transaction structure, and closing conditions have not been indexed in public media or regulator databases as of the research date. The NSE document link confirms the filing classification and timestamp.
Why it mattersRegulation 30 intimation confirms deal completion or announcement milestone; review the full filing PDF and company press release for material contract terms, price, earn-out conditions and integration timeline.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Announcements Archive · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026